首页> 美国卫生研究院文献>other >The CYP19 RS4646 Polymorphism IS Related to the Prognosis of Stage I–II and Operable Stage III Breast Cancer

【2h】

The CYP19 RS4646 Polymorphism IS Related to the Prognosis of Stage I–II and Operable Stage III Breast Cancer

机译：CYP19 RS4646多态性与I–II期和可手术III期乳腺癌的预后有关

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposeAromatase, encoded by the CYP19 gene, catalyzes the final step of the conversion of androgens to estrogens. Given the critical role of CYP19 in estrogen synthesis, the potential influence of CYP19 rs4646 polymorphism on breast cancer survival, deserves further study.

机译：目的由CYP19基因编码的芳香酶催化雄激素转化为雌激素的最后一步。鉴于CYP19在雌激素合成中的关键作用，CYP19 rs4646多态性对乳腺癌生存的潜在影响值得进一步研究。

著录项

期刊名称 other
作者
Xiying Shao; Yong Guo; Xiaohong Xu; Yabing Zheng; Jiwen Wang; Zhanhong Chen; Jian Huang; Ping Huang; Jufen Cai; Xiaojia Wang;
展开▼
作者单位

展开▼
年(卷),期 -1(10),3
年度 -1
页码 e0121535
总页数 13
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers. [J] . Huang CS, Kuo SH, Lien HC, The oncologist . 2008,第7期

机译：CYP19 TTTA重复多态性与绝经前I-II期和可手术III期乳腺癌的预后有关。
2. Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage I-II and operable stage III breast cancer [J] . Shao Xiying, Luo Lei, Guo Yong, Oncology letters . 2017,第5aPta2期

机译：CYP19A1基因的Rs1008805多态性与激素治疗在第I-II期和可操作阶段III乳腺癌中的疗效相关
3. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. [J] . Horiguchi J, Oyama T, Takata D, Anticancer Research: International Journal of Cancer Research and Treatment . 2011,第9期

机译：接受新辅助紫杉醇和曲妥珠单抗联合或不联合蒽环类药物治疗II和III期，HER2阳性可手术性乳腺癌的患者的完整病理学和预后：单次研究。
4. Early Assessment of the Added Value of FDG-PET/CT and MRI-DWI in Monitoring Treatment Response of Stage III Non-Small Cell Lung Cancer [C] . K.R. Siegersma, J.M. Hummel, H. Broekhuizen Mediterranean Conference on Medical and Biological Engineering and Computin . 2016

机译：早期评估FDG-PET / CT和MRI-DWI的增加值监测III期非小细胞肺癌的治疗响应
5. The effectiveness of chemoradiation for stage III non-small-cell lung cancer patients at the Kingston Regional Cancer Center (Ontario). [D] . Sinclair, Suzanne Marie. 2003

机译：金斯敦地区癌症中心（安大略省）对III期非小细胞肺癌患者进行化学放射治疗的有效性。
6. Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage I–II and operable stage III breast cancer [O] . Xiying Shao, Lei Luo, Yong Guo, -1

机译：CYP19A1基因的Rs1008805多态性与激素治疗I–II期和可手术III期乳腺癌的疗效相关
7. The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer. [O] . Xiying Shao, Yong Guo, Xiaohong Xu, 2015

机译：CYp19 Rs4646多态性与I-II期和可手术III期乳腺癌的预后相关。

The CYP19 RS4646 Polymorphism IS Related to the Prognosis of Stage I–II and Operable Stage III Breast Cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅